Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tokai appoints CMO and VP of medical development

This article was originally published in Scrip

Executive Summary

Tokai, a biopharmaceutical firm specialising in prostrate cancer treatments, has appointed Adrian M. Senderowicz as its chief medical officer and vice-president of medical development. Dr Senderowicz has previously served as medical director of oncology clinical development at AstraZeneca. In this role he oversaw the US FDA approval of Caprelsa (vandetanib) for advanced medullary thyroid carcinoma. Before joining AstraZeneca, he held various senior positions at the FDA Division of Oncology Drug Products in the Center for Drug Evaluation and Research. Tokai says that Dr Senderowicz brings valuable expertise to the development of its lead candidate, galeterone (TOK-001), which recently won an FDA fast-track designation from for metastatic castration-resistant prostate cancer.

You may also be interested in...



Future Unclear For EU Mandatory Joint Clinical Assessment Plans

Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.

Ibrance Joins Rival CDK4/6 Inhibitors In English Cancer Drugs Fund

Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.

Brazilian Regulator Wins Place On ICH Management Committee

Brazil’s pharmaceutical industry has welcomed the election of medicines regulator ANVISA to the management committee of the International Council for Harmonization.

Topics

Related Companies

UsernamePublicRestriction

Register

SC018436

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel